Due to popular demand we will offer a re-run of this webinar. The presentation takes place on Wednesday November 12th  between 16.00 and 16.30 CET / 15.00-15.30 GMT / 10.00-10.30 AM EST / 7.00-7.30 AM PST.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Oligonucleotide-based drugs, such as antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), have emerged as promising therapeutic solutions for central nervous system (CNS) diseases. However, they can trigger unexpected CNS-related adverse events in vivo, that can appear within hours to several weeks after administration.

One way to accelerate the development of safe therapeutic oligonucleotide-based drugs is to front-load neurotoxicity testing by using predictive high-capacity in vitro assays early in the discovery stage. Cellectricon has developed a broad range of assays for assessing drug effects  on e.g. neuronal function, cellular phenotype, and the immune response.

In this webinar, we explore the utility of some of these assays for neurotoxicity testing of oligonucleotide-based drugs. We will provide an overview of the assays evaluated, and how these may be applied to detect both acute and delayed onset oligonucleotide-induced toxicity.

Presented by:

Paul Karila, CBO

Paul joined the company in 2012 as head of Cellectricon’s Discovery Services and is now responsible for deal-making and business development in his role as CBO. He previously worked at AstraZeneca (AZ) where he held leadership positions at the Departments of Molecular Pharmacology and Neuroscience. At AZ, Paul led teams responsible for target identification/target validation and ion channel and GPCR profiling in LI-LO phase, mainly in chronic pain and neuropsychiatry projects. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, USA, studying neurobiology using electrophysiological methods. He has a PhD in physiology from University of Gothenburg, Sweden.